CD4+FoxP3+ regulatory T cells (Treg) constitutively express high levels of GITR and GITR ligation breaks self-tolerance and abrogates T cell suppression by Treg, thus providing the rationale to target GITR for cancer immunotherapy [7, 10]. The gene discussed is TNFRSF18; the disease is cancer.